Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial 2021-06-04 02:00
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China 2021-01-09 11:06
1